Cabazitaxel

Next > >

Cabazitaxel

<< Previous

Send Inquiry

Product Code : #0060

Brand Name : Jevtana

Product Specifications

Formulations Type
Injectables
Formulations Form
Liquid

Gender/Age Group
Adult

Product Description

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.^[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.^[2]^{[unreliable source?]}

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Trade Information

Payment Terms
Cash on Delivery (COD), Cash Advance (CA), Delivery Point (DP), Western Union
Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa